Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
Scientific Reports|April 3, 2022
A whole genome sequencing study of moderate to severe asthma identifies a lung function locus associated with asthma riskDiana Chang, Julie Hunkapiller, Tushar Bhangale, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|September 10, 2020
A randomized, placebo-controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER)Cary D Austin, Melissa Gonzalez Edick, Ronald E Ferrando, et al.
The European Respiratory Journal|September 25, 2021
Factors affecting adherence with treatment advice in a clinical trial of patients with severe asthmaJohn Busby, John G Matthews, Rekha Chaudhuri, et al.
American Journal of Respiratory and Critical Care Medicine|May 13, 2022
Exacerbation Profile and Risk Factors in a Type-2-Low Enriched Severe Asthma Cohort: A Clinical Trial to Assess Asthma Exacerbation PhenotypesP Jane McDowell, John Busby, Catherine E Hanratty, et al.
Science Translational Medicine|August 21, 2015
TH2 and TH17 inflammatory pathways are reciprocally regulated in asthmaDavid F Choy, Kevin M Hart, Lee A Borthwick, et al.
The Journal of Allergy and Clinical Immunology. in Practice|January 9, 2023
A Randomized Trial of a Composite T2-Biomarker Strategy Adjusting Corticosteroid Treatment in Severe Asthma: A Post Hoc Analysis by SexMatthew C Eastwood, John Busby, David J Jackson, et al.
The Lancet. Respiratory Medicine|September 11, 2020
Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trialLiam G Heaney, John Busby, Catherine E Hanratty, et al.
Trials|January 6, 2018
A randomised pragmatic trial of corticosteroid optimization in severe asthma using a composite biomarker algorithm to adjust corticosteroid dose versus standard care: study protocol for a randomised trialCatherine E Hanratty, John G Matthews, Joseph R Arron, et al.
The Journal of Allergy and Clinical Immunology|June 14, 2023
Blood transcriptomic signature in type-2 biomarker-low severe asthma and asthma controlXue Zeng, Jing Qing, Chi-Ming Li, et al.
The Journal of Allergy and Clinical Immunology|April 29, 2022
Genome-wide association study identifies kallikrein 5 in type 2 inflammation-low asthmaJanet K Jackman, Amy Stockwell, David F Choy, et al.
Pageof 7